GlassScriptPhysician profile
Steve Edward Savinoff
NPI 1114546058
$3,820.15
in general payments reported to CMS, 2019-2025
29 companies · $1,904 in 2025
The $1,904 reported for 2025 was more than what 77% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $150 · 2024: $1,767 · 2025: $1,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,345 · Travel and Lodging: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,345.33 |
| Travel and Lodging | $474.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $1,738.36 | 2024-2025 | |
| Abbvie INC. | $387.77 | 2025 | |
| Livanova USA, INC. | $313.86 | 2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Sk Life Science, INC. | $227.37 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $151.93 | 2025 | |
| Jazz Pharmaceuticals INC. | $96.26 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $87.28 | 2025 | Austedo Xr |
| Neurelis, INC. | $76.76 | 2025 | Valtoco |
| Janssen Biotech, INC. | $68.96 | 2025 | |
| Lilly USA, LLC | $65.37 | 2025 | Kisunla |
| Genzyme Corporation | $60.48 | 2025 | |
| Lundbeck LLC | $59.77 | 2025 | Vyepti |
| Celgene Corporation | $55.15 | 2025 | Zeposia |
| Otsuka America Pharmaceutical, INC. | $51.64 | 2025 | Rexulti |
| Alexion Pharmaceuticals, INC. | $43.85 | 2025 | Ultomiris |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $34.97 | 2025 | |
| Ucb, INC. | $30.42 | 2025 | Rystiggo |
| Axsome Therapeutics, INC. | $30.30 | 2025 | Symbravo |
| Argenx US, INC. | $29.40 | 2025 | Vyvgart Hytrulo |
| Ipsen Biopharmaceuticals, INC | $29.03 | 2025 | Dysport |
| Emd Serono, INC. | $28.94 | 2025 | |
| Cycle Pharmaceuticals INC | $25.02 | 2025 | Tascenso Odt, Bafiertam |
| Genentech USA, INC. | $24.59 | 2025 | Ocrevus Zunovo |
| Csl Behring | $22.64 | 2025 | Hizentra |
| Biogen, INC. | $17.24 | 2025 | Vumerity |
| Tanabe Pharma America, INC. | $17.06 | 2025 | Radicava |
| Pfizer INC. | $15.89 | 2025 | |
| Amneal Pharmaceuticals LLC | $15.39 | 2025 | Brekiya |
| Astrazeneca Pharmaceuticals LP | $14.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Savinoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.